Related News
Home » Metro » Health and Science
New drug brings relief to orthopedic patients
By Cai Wenjun |
April 16, 2013, Tuesday
|
Online Edition
Online Edition
AN innovative medicine is shown capable of preventing blood clots in the veins of patients who just received hip or knee replacement surgery. The new drug is now available in the Chinese market.
Made by Bristol-Myers Squibb and Pfizer, Eliquis can reduce the risk of venous thromboembolism (VTE) that occurs in some 60 percent of patients with major orthopedic surgeries seven to 14 days later.
VTE is also referred to as deep vein thrombosis if it clots leg veins or pulmonary embolism if it blocks lung arteries, doctors said.
Eliquis has been widely used in the Western countries and its import is a relief for patients in China where about 400,000 hip or knee replacement surgeries are performed each year, doctors said.
Made by Bristol-Myers Squibb and Pfizer, Eliquis can reduce the risk of venous thromboembolism (VTE) that occurs in some 60 percent of patients with major orthopedic surgeries seven to 14 days later.
VTE is also referred to as deep vein thrombosis if it clots leg veins or pulmonary embolism if it blocks lung arteries, doctors said.
Eliquis has been widely used in the Western countries and its import is a relief for patients in China where about 400,000 hip or knee replacement surgeries are performed each year, doctors said.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
